Search results
In August 2025, 8-year-old Rose Earnshaw is taking on a challenge like no other – completing 5 laps of her local village park (1 mile) every day throughout the month of August, in support of Retina UK’s vital work.
As part of Retina UK's birthday celebrations, we would love for you to face your fears by taking on a skydive for us!
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP
This July, Ben Ramus will lead a group of twelve adventurers as they take on the renowned National Three Peaks Challenge, in aid of national sight loss charity, Retina UK. Ben has decided to take on the epic challenge in recognition of two of his uncles’ sight loss journey, as they live with the rare inherited sight loss condition, retinitis pigmentosa.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).
The following projects were being funded by Retina UK and have recently come to an end.
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.
Prof Mariya Moosajee at Moorfields Eye Hospital has asked us to share the message below about the clinical trial she is running. This trial is for a treatment that targets a particular section of the USH2A gene.
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
